[Corrigendum] Use of methylation profiling to identify significant differentially methylated genes in bone marrow mesenchymal stromal cells from acute myeloid leukemia.
{"title":"[Corrigendum] Use of methylation profiling to identify significant differentially methylated genes in bone marrow mesenchymal stromal cells from acute myeloid leukemia.","authors":"Jing Huang, Zhi Liu, Yufan Sun, Qi Zhong, Li Xu, Ruimin Ou, Cheng Li, Rui Chen, Mengdong Yao, Qing Zhang, Shuang Liu","doi":"10.3892/ijmm.2025.5520","DOIUrl":null,"url":null,"abstract":"<p><p>Following the publication of the above article, an interested reader drew to the authors' and the Editor's attention that, given the subject matter of the article, in a few places in the text throughout the paper, 'MIR159' was probably intended to have been written as 'MIR596', and 'miR‑159' was probably meant to have been written as 'miR‑596'. The authors have responded to confirm that the interested reader was correct in their assessment; this paper discusses the role of miR‑596 in the context of acute myeloid leukemia (AML) and its potential as a biomarker, and this error appears to have occurred during the final stages of manuscript preparation. Therefore, the following corrections to the text of this article should be noted: a) In the final sentence of the Abstract on p. 679, 'miR‑596' should have been written, rather than 'miR‑159'. The corrected sentence should read as follows: 'Furthermore, the aberrantly hypermethylated <b>miR‑596</b>‑encoding gene <i><b>MIR596</b></i> may be a potential biomarker of AML.' b) In the Discussion, all instances where 'miR‑159' and 'MIR159' were mentioned should be corrected to 'miR‑596' and 'MIR596', respectively. The sentences concerned should have read as follows (p. 685, right‑hand column, line 9): 'Thus, it was suggested that the hypermethylation of <b>miR‑596</b> may be associated with its transcriptional regulation. It was also inferred that <b>miR‑596</b> methylation in BM‑MSCs may be a biomarker or prognostic factor for patients with AML. However, the significance of the methylation of miR‑596 demands further investigation.\" In addition, the sentence starting on p. 685, right‑hand column, second paragraph, line 5, should have read as follows: 'Furthermore, the aberrant hypermethylated <b>miR‑596</b>‑encoding gene <i><b>MIR596</b></i> may be a potential biomarker of AML.' All the authors agree with the publication of this corrigendum; furthermore, they also apologize to the readership of the journal for any inconvenience caused. [International Journal of Molecular Medicine 41: 679‑686, 2018; DOI: 10.3892/ijmm.2017.3271].</p>","PeriodicalId":14086,"journal":{"name":"International journal of molecular medicine","volume":"55 5","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11936481/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of molecular medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/ijmm.2025.5520","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/21 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Following the publication of the above article, an interested reader drew to the authors' and the Editor's attention that, given the subject matter of the article, in a few places in the text throughout the paper, 'MIR159' was probably intended to have been written as 'MIR596', and 'miR‑159' was probably meant to have been written as 'miR‑596'. The authors have responded to confirm that the interested reader was correct in their assessment; this paper discusses the role of miR‑596 in the context of acute myeloid leukemia (AML) and its potential as a biomarker, and this error appears to have occurred during the final stages of manuscript preparation. Therefore, the following corrections to the text of this article should be noted: a) In the final sentence of the Abstract on p. 679, 'miR‑596' should have been written, rather than 'miR‑159'. The corrected sentence should read as follows: 'Furthermore, the aberrantly hypermethylated miR‑596‑encoding gene MIR596 may be a potential biomarker of AML.' b) In the Discussion, all instances where 'miR‑159' and 'MIR159' were mentioned should be corrected to 'miR‑596' and 'MIR596', respectively. The sentences concerned should have read as follows (p. 685, right‑hand column, line 9): 'Thus, it was suggested that the hypermethylation of miR‑596 may be associated with its transcriptional regulation. It was also inferred that miR‑596 methylation in BM‑MSCs may be a biomarker or prognostic factor for patients with AML. However, the significance of the methylation of miR‑596 demands further investigation." In addition, the sentence starting on p. 685, right‑hand column, second paragraph, line 5, should have read as follows: 'Furthermore, the aberrant hypermethylated miR‑596‑encoding gene MIR596 may be a potential biomarker of AML.' All the authors agree with the publication of this corrigendum; furthermore, they also apologize to the readership of the journal for any inconvenience caused. [International Journal of Molecular Medicine 41: 679‑686, 2018; DOI: 10.3892/ijmm.2017.3271].
期刊介绍:
The main aim of Spandidos Publications is to facilitate scientific communication in a clear, concise and objective manner, while striving to provide prompt publication of original works of high quality.
The journals largely concentrate on molecular and experimental medicine, oncology, clinical and experimental cancer treatment and biomedical research.
All journals published by Spandidos Publications Ltd. maintain the highest standards of quality, and the members of their Editorial Boards are world-renowned scientists.